Surgery for Cataract Patients with Glaucoma
Serving Philadelphia, Conshohocken, the Main Line, King of Prussia, Northeast Philadelphia and Phoenixville
Hydrus MicroStent, iStent, iStent Inject, GATT, Goniotomy, and Ab Interno Canaloplasty have revolutionized the management of cataract patients with mild to moderate glaucoma. The FDA has approved these techniques for the treatment of mild to moderate glaucoma at the time of cataract extraction.
We now perform Hydrus exclusively in appropriate cases of cataract with mild to moderate glaucoma. Our clinical results, in more than 200 procedures, are superior to those achieved with the other modalities. Our statistics match the three year peer-reviewed literature (Horizon Study) in which 80% of single drop glaucoma patients could safely stop their pressure lowering drops following Cat/Hydrus. More importantly, this landmark study showed a significant reduction in significant glaucoma progression (versus non-MIGS patients) thereby reducing the need for secondary invasive glaucoma surgery following three years of clinical observation.
First in the Pennsylvania, New Jersey, Delaware & Maryland to Perform The Hydrus Procedure
Dr. Lewis is the first in the area to perform this glaucoma surgery.
The procedure required to implant the Hydrus® Microstent is designed to be quick, less invasive, and performed in conjunction with cataract surgery. Doctors can now, using the unique delivery system, implant a Hydrus Microstent through the very small incisions needed for cataract surgery. No additional incisions are necessary (unlike many of the more traditional surgical procedures used to treat glaucoma). This significantly less invasive approach is called “ab-interno”, and may lead to fewer complications and faster healing times than traditional glaucoma surgery. Following cataract surgery, the Hydrus Microstent is inserted into the outflow canal of your eye, called “Schlemm’s canal.” Normally, you will not be able to see or feel the tiny device in place following your procedure.
